Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Several classes of pharmacological agents have demonstrated benefits in hypertensive patients with CAD, but most published studies have, of necessity, enrolled only patients with an elevated or borderline elevated blood pressure. Recent clinical trials have demonstrated benefits for both angiotensin-converting enzyme inhibitors and calcium channel blockers (in patients with coronary artery disease with relatively normal or borderline elevated blood pressures.

What’s the Correct BP to Reduce Adverse CV Events?